Brought to you by 
Bristol gets option to acquire Promedior for up to $1.25bn; withdrawn
20 Nov 2019
Executive Summary
Bristol-Myers Squibb Co. received the exclusive right to buy Promedior Inc., a private rare fibrotic disease drug developer. BMS pays $150mm up front (covering the right to acquire and for Phase II-related support services); an option exercise fee; and clinical and regulatory earn-outs. In all, the deal could be worth up to $1.25bn.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bristol gets option to acquire Promedior for up to $1.25bn; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice